Strategic analysis for a not-for-profit biopharmaceutical enterprise

Two Vancouver scientists, using proteomic methods, identified key antigens to confer resistance to Chlamydia trachomatis. They created a prophylactic and therapeutic vaccine for sexually transmitted C. trachomatis infections. The inventors aim to commercialize this new product. This strategic analysis presents competitive and internal analyses. An evaluation of strategic alternatives based on these analyses follows. The inventors intend for the public at large, and not the shareholders, to receive the benefits of the product. This report proposes a strategic plan that fits the inventors’ goals. Market entry strategies and a business plan will evolve from the strategic analysis. This strategic analysis provides the British Columbia Centre for Disease Control (BCCDC) information to help them decide on a business development strategic plan for Canada, the United States, and developing country markets.